Cancer Immunotherapy: choose your fighter!

Immunotherapy has revolutionized cancer treatment by unleashing immune system against tumors

The immune system can recognize and kill abnormal cells, including cancer cells, but tumors often develop mechanisms to evade immune system. Immunotherapy works by enforcing the immune response or removing the barriers that prevent the immune system from attacking cancer cells effectively. Various types of immunotherapies are being developed, including checkpoint inhibitors, CAR-T and TCR-T cell therapy, CAR-NK cell therapy, bivalent or multi-specific immune cell engagers, engineered cytokines, and cancer vaccines. These treatments have shown remarkable success in certain cancers, offering the potential for long-lasting and targeted responses with fewer side effects compared to traditional therapies.

Despite the promising advancements in immunotherapy, challenges remain, including identifying the most effective approaches for different types of cancer and managing potential side effects. Ongoing research continues to explore novel immunotherapeutic strategies and combination therapies to enhance the overall effectiveness of cancer treatment and improve outcomes for patients. As the field evolves, immunotherapy holds great promise for transforming the landscape of cancer care and providing new hope for individuals facing this challenging disease.

Discover our enabling solutions to advance immunotherapy and cancer research areas!

Engineering T & NK Cells for Adoptive Cell Therapy

The development of CAR-expressing T cells led to huge progress in the treatment of some types of cancer, with potential for applications in transplantation and autoimmunity. Engineered CAR-NK cells also hold promise for improved therapies. In addition, cancer-targeting TCRs may provide expanded adoptive cell therapy options. The future is bright for CAR-T and TCR-T cell research, and BPS Bioscience continues to develop unique cell lines and other tools to help researchers create, evaluate, and enhance immune cells for the improvement of human health.

www.bpsbioscience.com/car-t

www.bpsbioscience.com/antigen-specific-tcr

BPS Bioscience solutions support critical steps in CAR-T and CAR-NK cell therapy research and development spanning from creation of CAR-T cells through functional testing and validation, according the workflow below.

Learn more about custom products and services!

We can also help you design your CAR and generate CAR cells from start to finish.

Learn more about custom CAR-T cell development!

ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Derived from the Nobel Prize-winning work of Dr. James P. Allison and Dr. Tasuku Honjo, immune checkpoint inhibitors were identified to be the key regulators of the immune system.  These drugs are meant to prevent an ‘OFF’ signal from tumor cells that can block the activity of the immune system. But what if the immune response just isn’t enough?

Agonists, otherwise called stimulatory checkpoint molecules can ‘hit the gas’ maximizing the immune response.  This implies the use of multiple costimulatory molecules to activate T cell response. For example, B7-CD28 signaling is a major costimulatory signaling cascade contributing to T-cell activation and cytokine release. 4-1BB, OX40, glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR) and other receptors in the TNF superfamily can synergize with TCR signaling to enhance T-cell responses and survival. To date, agonists of co-stimulatory receptors of the tumor necrosis factor superfamily (TNF-SF) and B7 family are emerging as promising options to expand the immunomodulatory toolbox.

ACROBiosystems has developed a series of products targeting immune co-stimulatory molecules of TNFSF and B7-CD28 family, including proteins, overexpression cell lines, and inhibitor screening kits. All products are verified and validated, not only as a final product, but starting from antibody preparation, initial screening, production to quality control; ensuring the best reagents and tools to develop your agonist immunotherapies.

Click to learn more immune checkpoint molecules

Creative Biolabs distributes biosimilar development with advanced technology platforms and professionals. To boost your biosimilar research programs, Creative Biolabs provides a full range of engineered antibodies currently available for disease research. We also have many other types of antibodies and protein products. With rich experience for over 10 years, Creative Biolabs offer high quality products that will meet your any requirement.

Purchase all these products through DBA Italia